Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| SUM1315MO2 | Alvocidib | 1.0 | -0.6503 | 0.31385 |
| MCF 10A | THZ1 | 1.0 | -0.6472 | 0.79801 |
| HCC1500 | THZ531 | 0.1 | -0.6465 | -0.05699 |
| HCC70 | Alvocidib | 0.316227766 | -0.6458 | 0.39950 |
| MDA-MB-157 | THZ1 | 0.1 | -0.6453 | 0.31864 |
| HCC70 | THZ531 | 0.316227766 | -0.6438 | 0.45728 |
| SK-BR-3 | THZ531 | 1.0 | -0.6438 | 0.28730 |
| MDA-MB-361 | THZ531 | 0.316227766017 | -0.6421 | 0.17433 |
| HCC70 | Alvocidib | 0.316227766 | -0.6414 | 0.31649 |
| BT-20 | MK 1775 | 10.0 | -0.6391 | 0.52329 |
| MDA-MB-157 | THZ1 | 0.1 | -0.6387 | 0.28180 |
| HCC1500 | GSK2334470 | 3.16227766017 | -0.6375 | -0.15054 |
| HCC1500 | MK 1775 | 1.0 | -0.6375 | -0.06462 |
| HCC1428 | AZD2014 | 3.16227766 | -0.6349 | -0.03703 |
| SK-BR-3 | THZ1 | 0.1 | -0.6338 | 0.30104 |
| SUM1315MO2 | Alvocidib | 1.0 | -0.6312 | 0.30727 |
| MDA-MB-157 | THZ531 | 0.316227766017 | -0.6298 | 0.32110 |
| MDA-MB-361 | THZ1 | 1.0 | -0.6297 | 0.11823 |
| HCC1395 | Alvocidib | 1.0 | -0.6278 | 0.29534 |
| MDA-MB-134-VI | LY3023414 | 0.316227766017 | -0.6274 | 0.14189 |
| BT-20 | MK 1775 | 10.0 | -0.6247 | 0.40190 |
| HCC1395 | Alvocidib | 1.0 | -0.6242 | 0.20537 |
| MCF 10A | THZ531 | 1.0 | -0.6240 | 0.88272 |
| HCC1428 | Rucaparib | 3.16227766 | -0.6236 | 0.06920 |
| SK-BR-3 | THZ1 | 0.316227766017 | -0.6215 | 0.28329 |